084650 — Labgenomics Co Balance Sheet
0.000.00%
- KR₩171bn
- KR₩114bn
- KR₩73bn
- 51
- 36
- 16
- 21
Annual balance sheet for Labgenomics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 14,062 | 53,085 | 98,898 | 136,871 | 115,391 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 18,475 | 31,654 | 68,495 | 35,552 | 41,154 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 33,607 | 87,526 | 170,931 | 174,483 | 160,378 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7,440 | 7,987 | 19,698 | 54,885 | 54,957 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 49,478 | 109,364 | 204,287 | 250,653 | 313,457 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10,625 | 25,016 | 40,683 | 19,896 | 65,055 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 19,061 | 27,820 | 46,571 | 41,322 | 85,662 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 30,417 | 81,543 | 157,715 | 209,331 | 227,795 |
Total Liabilities & Shareholders' Equity | 49,478 | 109,364 | 204,287 | 250,653 | 313,457 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |